Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Feb 14;2(1):112-28.
doi: 10.3390/vaccines2010112.

Towards New Broader Spectrum Pneumococcal Vaccines: The Future of Pneumococcal Disease Prevention

Lucia H Lee  1 , Xin-Xing Gu  2 , Moon H Nahm  3
Affiliations
Review

Towards New Broader Spectrum Pneumococcal Vaccines: The Future of Pneumococcal Disease Prevention

Lucia H Lee et al. Vaccines (Basel). .

Abstract

Seven-valent pneumococcal conjugate vaccine (PCV7) introduction and routine pediatric use has substantially reduced the burden of Streptococcus pneumoniae disease worldwide. However, a significant amount of disease burden, due to serotypes not contained in PCV7, still exists globally. A newly recognized serotype, 6C, was until recently, identified and reported as serotype 6A. This review summarizes the serotype epidemiology of pneumococcal disease pre- and post-introduction of PCV7, available post-marketing surveillance data following the introduction of higher valency pneumococcal vaccines (PCV10, PCV13) and future prospects for the development of new pneumococcal vaccines.

Keywords: Streptococcus pneumoniae; epidemiology; pneumococcal protein; serotype; vaccine.

PubMed Disclaimer

References

    1. McIntosh E.D., Reinert R.R. Global prevailing and emerging pediatric pneumococcal serotypes. Expert Rev. Vaccines. 2011;10:109–129. - PubMed
    1. Munoz-Almagro C., Jordan I., Gene A., Latorre C., Garcia-Garcia J.J., Pallares R. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin. Infect. Dis. 2008;46:174–182. doi: 10.1086/524660. - DOI - PubMed
    1. Kaplan S.L., Mason E.O., Jr., Wald E.R., Schutze G.E., Bradley J.S., Tan T.Q., Hoffman J.A., Givner L.B., Yogev R., Barson W.J., et al. Decrease of invasive pneumococcal infections in children among 8 children’s hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics. 2004;113:443–449. doi: 10.1542/peds.113.3.443. - DOI - PubMed
    1. Weil-Olivier C., van der Linden M., de Schutter I., Dagan R., Mantovani L. Prevention of pneumococcal diseases in the post-seven valent vaccine era: A European perspective. BMC Infect. Dis. 2012;12:e207. doi: 10.1186/1471-2334-12-207. - DOI - PMC - PubMed
    1. Williams S.R., Mernagh P.J., Lee M.H., Tan J.T. Changing epidemiology of invasive pneumococcal disease in Australian children after introduction of a 7-valent pneumococcal conjugate vaccine. Med. J. Aust. 2011;194:116–120. - PubMed